Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V. Bellutti F, et al. Among authors: sexl v. Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13. Cancer Discov. 2018. PMID: 29899063 Free PMC article.
JunB is a gatekeeper for B-lymphoid leukemia.
Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zöchbauer S, Wagner EF, Freissmuth M, Sexl V. Ott RG, et al. Among authors: sexl v. Oncogene. 2007 Jul 19;26(33):4863-71. doi: 10.1038/sj.onc.1210285. Epub 2007 Feb 12. Oncogene. 2007. PMID: 17297445
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V. Warsch W, et al. Among authors: sexl v. Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10. Blood. 2011. PMID: 21220747 Free article.
The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.
Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, Stoiber D, Sexl V. Schuster C, et al. Among authors: sexl v. Blood. 2011 Oct 27;118(17):4635-45. doi: 10.1182/blood-2010-10-313098. Epub 2011 Aug 30. Blood. 2011. PMID: 21878673 Free article.
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.
Putz EM, Prchal-Murphy M, Simma OA, Forster F, Koenig X, Stockinger H, Piekorz RP, Freissmuth M, Müller M, Sexl V, Zebedin-Brandl E. Putz EM, et al. Among authors: sexl v. PLoS One. 2012;7(7):e40852. doi: 10.1371/journal.pone.0040852. Epub 2012 Jul 13. PLoS One. 2012. PMID: 22808277 Free PMC article.
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. Laimer D, et al. Among authors: sexl v. Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14. Nat Med. 2012. PMID: 23064464 Free article.
205 results